We are live on ! Find out more
ES

Enavate Sciences Portfolio holdings

AUM $352M
1-Year Est. Return 220.14%
This Fund
S&P 500
This Quarter Est. Return
-35.01%
1 Year Est. Return
+220.14%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$139M
AUM Growth
–
Cap. Flow
+$200M
Cap. Flow %
143.4%
Top 10 Hldgs %
100%
Holding
5
New
5
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
ZBIO
Zenas BioPharma
ZBIO
+$58.7M
2
UPB
Upstream Bio Inc
UPB
+$54.9M
3
IMNM icon
Immunome
IMNM
+$42M
4
CAMP icon
CAMP4 Therapeutics
CAMP
+$31.1M
5
CMPX icon
Compass Therapeutics
CMPX
+$12.9M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
UPB
1
Upstream Bio Inc
UPB
$352M
$40.4M 29.04%
+2,459,703
New +$54.9M
IMNM icon
2
Immunome
IMNM
$2.63B
$36.9M 26.53%
+3,478,261
New +$42M
ZBIO
3
Zenas BioPharma
ZBIO
$2.04B
$30.8M 22.12%
+3,761,359
New +$58.7M
CAMP icon
4
CAMP4 Therapeutics
CAMP
$181M
$19.8M 14.19%
+3,785,802
New +$31.1M
CMPX icon
5
Compass Therapeutics
CMPX
$367M
$11.3M 8.11%
+7,788,150
New +$12.9M

Similar funds

HIA
HTG Investment Advisors New Canaan, Connecticut $352M AUM 17.26% 1-Year Est. Return
AW
Alaethes Wealth Glenbrook, Nevada $351M AUM 22.79% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
PIC
PCJ Investment Counsel Toronto, Ontario, Canada $352M AUM 68.32% 1-Year Est. Return
FFO
Fiduciary Family Office Boca Raton, Florida $351M AUM 22.19% 1-Year Est. Return
EC
Elmind Capital New York $352M AUM
SMC
Spider Management Company Richmond, Virginia $351M AUM 18.35% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Enavate Sciences's Q4 2024 Portfolio in Review

Q4 2024 is the first quarter with a 13F filing on record for Enavate Sciences, which disclosed 5 positions worth $139M. Its ten largest holdings account for 100% of the portfolio.

Its largest position is Zenas BioPharma: 3,761,359 shares worth $30.8M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets.

  • Enavate Sciences's largest Q4 2024 buy was Zenas BioPharma: 3,761,359 shares worth $30.8M.
  • Enavate Sciences's ten largest holdings make up 100% of its $139M portfolio in Q4 2024.
  • Enavate Sciences disclosed 5 positions in Q4 2024, its first 13F filing on record.

Based on Enavate Sciences's 13F filing for Q4 2024, filed 14 Feb 2025.